Pessary Experience Study

Sponsor
University of Virginia (Other)
Overall Status
Recruiting
CT.gov ID
NCT06021769
Collaborator
(none)
30
1
17.7
1.7

Study Details

Study Description

Brief Summary

Pessaries are silicone devices inserted into the vagina for treatment of pelvic organ prolapse or stress urinary incontinence. They are adequate treatment options for patients who are poor surgical candidates, those who decline surgical intervention, or as a temporizing measure in those ultimately planning surgery. Most studies suggest that about 75% of patients are able to be successfully fit with a pessary, but about 50% discontinue pessary use within 12 months of initiation. The purpose of this study is to determine why pessaries are discontinued.

Condition or Disease Intervention/Treatment Phase
  • Other: Observational only

Detailed Description

Pessaries are silicone devices inserted into the vagina for treatment of pelvic organ prolapse or stress urinary incontinence. They are adequate treatment options for patients who are poor surgical candidates, those who decline surgical intervention, or as a temporizing measure in those ultimately planning surgery. Most studies suggest that about 75% of patients are able to be successfully fit with a pessary, but about 50% discontinue pessary use within 12 months of initiation.

Research concerning pessary discontinuation is currently focused on identifying factors that will predict outcomes of pessary use. It is generally agreed upon that pessaries are one of the favored option to conservatively treat pelvic organ prolapse or stress urinary incontinence, but there is not sufficient consensus on the rate of discontinuation, factors leading to discontinuation, and patient satisfaction.

Most studies recorded reasons for discontinuation and any adverse events. Patients' reasons for discontinuation of pessary use included frequent expulsion, difficulty removing pessary, new or worsening urinary incontinence, vaginal erosion, and pain/discomfort1, 2, 3. Significant side effects or adverse events included vaginal discharge and erosion1, 2, 3

Several studies focused on anatomic and medical variables that were correlated to pessary discontinuation. A univariate analysis of factors contributing to discontinuation conducted by Yimphong et al.1 found that higher BMI and history of pelvic surgery were significant in predicting discontinuation. Similarly, Panman2 et al. conducted a multivariate analysis that found higher BMI was a significant factor. Panman et al. also found that both younger age and weaker pelvic floor muscles were predictors for discontinuation. The former finding is further supported by Umchanger et al.3, which cited that 33% of patients who discontinued pessary use within three months were generally less than 65 years. Umchanger et al. hypothesized that despite data suggesting that pessaries are as effective as surgery, younger patients may maintain the misconception that pessaries are not as effective.

Despite the data suggesting contributing factors such as BMI and age, none of the reviewed studies captured the qualitative reasoning behind patients' decisions. Only a few of the studies investigate patients' satisfaction with pessary use, quality of life, or opinion on their treatment.

Pessary use has been correlated to a wide variety of factors, such as a patient's medical history, anatomic characteristics, beliefs about pessary use, and personal satisfaction with treatment. Based on this review, a qualitative analysis of patient experience and priorities as they decide to continue or discontinue pessary use would be incredibly helpful for counseling and educating future patients when they are making treatment decisions about pessaries.

Study Design

Study Type:
Observational
Anticipated Enrollment :
30 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Longitudinal Assessment of Pessary Experience
Actual Study Start Date :
Jun 12, 2023
Anticipated Primary Completion Date :
Dec 1, 2024
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Women being fitted with pessaries

Women being fitted with pessaries as standard of care will be eligible to participate. They will be asked to complete a recorded verbal interview and written questionnaires the day they have their pessaries fitted and at their follow-up clinic appointments at 4-6 weeks, 3 months, 6 months, and 12 months. Another recorded video interview will be completed at the 12 month appointment.

Other: Observational only
No intervention

Outcome Measures

Primary Outcome Measures

  1. Qualitative analysis [up to 1 year after pessary fitting]

    Perform a patient-centered, qualitative analysis of pessary discontinuation

  2. Pelvic Floor symptom improvement as related to quality of life [up to 1 year after pessary fitting]

    Assess changes in pelvic floor symptoms and quality of life before and after pessary use as measured by validated questionnaires

  3. Discontinuation of pessaries [up to 1 year after pessary fitting]

    Rates of discontinuation at 1 year

  4. Why do women discontinue using pessaries? [up to 1 year after pessary fitting]

    Factors significantly associated with discontinuation

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • English-speaking women aged 18 years or older

  • Choosing to undergo a pessary fitting for symptomatic pelvic organ prolapse and/or stress urinary incontinence at the University of Virginia Pelvic Medicine and Reconstructive Surgery clinic

  • Willingness and ability to comply with scheduled visits and study procedures.

  • Successful pessary fitting

Exclusion Criteria:
  • Pregnant women

  • Prisoners

  • Cognitively impaired

  • Non-English speaking subjects

  • Patients who cannot comply with pessary check visits

  • Active vaginal infection

  • Vaginal malignancy

  • Genitourinary tract fistula

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Virginia Charlottesville Virginia United States 22903

Sponsors and Collaborators

  • University of Virginia

Investigators

  • Principal Investigator: Monique Vaughan, MD, Assistant Professor

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Monique Vaughan, MD, Assistant Professor, University of Virginia
ClinicalTrials.gov Identifier:
NCT06021769
Other Study ID Numbers:
  • HSR220160
First Posted:
Sep 1, 2023
Last Update Posted:
Sep 1, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Monique Vaughan, MD, Assistant Professor, University of Virginia
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 1, 2023